drugset
drugset / Trial / NCT06084416

A Study of Sovilnesib in Subjects With Ovarian Cancer

NCT06084416 ↗

Phase 1 Active not recruiting 120 enrolled Volastra Therapeutics, Inc.
RandomizedParallel-groupOpen-labelTreatment

Summary

This is a randomized, phase 1b study to assess the safety, tolerability, pharmacokinetics (PK), and efficacy of sovilnesib at different dose levels to establish the Recommended Phase 2 Dose (RP2D) of sovilnesib in subjects with high grade serous ovarian cancer (HGSOC).

Timeline

Start
2024-04-04
Primary completion
2026-03
Completion
2026-04

Drugs

EvaluationDrugModalityDoseRoute
Subject AMG 650 Small molecule — Oral

Indications

fallopian tube cancer ovarian serous adenocarcinoma primary peritoneal carcinoma